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Summary The definition of pulmonary fungal infections (PFI) according to the EORTC-MSG cri-
teria may lack diagnostic sensitivity due to the possible presentation of PFI with dif-
ferent radiological pictures. We evaluated the hypothesis to apply less restrictive
radiological criteria to define PFI in patients with acute myeloid leukaemia (AML)
submitted to chemotherapy. Overall, 73 consecutive episodes of pulmonary infiltrates
associated to positive serum galactomannan test or fungal isolation or galactoman-
nan detection from respiratory specimens were considered. CT scans acquired at the
onset of symptoms (time-0) and within 4 weeks (time-1) were analysed to identify
specific (group A) or aspecific radiological signs (group B). Pulmonary infiltrates ful-
filled the EORTC-MSG criteria in 49 patients (group A), whereas in 24 patients
(group B) they did not reach the criteria due to aspecific CT findings at time-0. Ele-
ven of 21 (52.4%) patients of the group B evaluable for the evolution of the radio-
logical findings fulfilled EORTC-MSG criteria at time-1. All the analysed clinical and
mycological characteristics, response to antifungal therapy and survival were compa-
rable in the two groups. Our study seems to confirm the possibility to extend the
radiological suspicion of PFI to less restrictive chest CT findings when supported by
microbiological criteria in high-risk haematological patients.
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Introduction
Pulmonary fungal infections (PFI), in particular inva-
sive pulmonary aspergillosis (IPA), are a major cause
of morbidity and mortality in patients affected by
acute myeloid leukaemia (AML).1–3 The European
Organization for Research and Treatment of Cancer
(EORTC) and the Mycosis Study Group (MSG) devel-
oped consensus definitions for the diagnosis of invasive
fungal diseases (IFD) in immunocompromised patients
to facilitate the identification of reasonably homoge-
neous groups of patients for clinical and epidemiologic
research and to foster communication between inter-
national researchers.4,5 Proven diagnosis of PFI neces-
sitates tissue microscopic visualisation of fungi.
However, the poor candidacy of many patients with
suspected PFI for invasive diagnostic procedures has
prompted interest in non-invasive means for diagnosis
and most of cases of PFI are documented at a level of
probable infection by radiological and microbiological
findings. According to the updated EORTC-MSG defini-
tions published in 2008, a diagnosis of probable PFI is
based on the documentation of at least 1 of 3 specific
radiological findings (dense, well-circumscribed lesions
with or without halo sign, air crescent sign or cavity)
associated with fungal isolation or galactomannan
(GM) detection from respiratory tract and/or positive
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serum GM or beta D glucan (BDG) assay.5 Although
the introduction of definitions for IFD has greatly facil-
itated the conduction of clinical trials on diagnostic
and therapeutic modalities, their diagnostic perfor-
mance in the clinical practice is low when compared
with autopsy examination.6–9 The application of speci-
fic but not very sensitive diagnostic radiological crite-
ria may determine an underestimation of these severe
complications as shown in recently published retro-
spective studies in patients affected by various haema-
tological diseases.10,11 As a consequence, the revision
of the EORTC-MSG definitions with the inclusion of
less specific radiological images in addition to the three
above findings in the diagnosis of PFI, when supported
by proper microbiological exams, has been pro-
posed.10–12 The objective of our study was to expand
the above experiences to a large homogeneous popula-
tion of high-risk AML patients submitted to standard
intensive chemotherapy.
Patients and methods
We retrospectively evaluated all consecutive patients
older than 18 years with a newly diagnosed non-M3
and BCR-ABL-negative AML, who underwent intensive
remission-induction chemotherapy at the Hematology
Departments of the Policlinico Umberto I of the
Sapienza University of Rome from February 2006
through December 2013. Informed consent for the use
of clinical data for scientific purposes had been
obtained from the patients. This was a non-interven-
tional retrospective study and the collection and stor-
age of data were performed by the investigators
directly involved in patient care using current tech-
niques of privacy assurance.
Patients were hospitalised in double-bed rooms with-
out air filtration or positive pressure. All patients under-
went a baseline chest CT scan at leukaemia diagnosis
and before any chemotherapy treatment. Antibacterial
prophylaxis consisted of oral ciprofloxacin
(500 mg bid1). Until March 2007 patients did not
receive any mould active systemic antifungal prophy-
laxis, while since April 2007 primary antifungal
prophylaxis with oral posaconazole (200 mg tid1) was
administered from the end of chemotherapy administra-
tion to the recovery of neutropenia, with the exception
of those treated with midostaurin, a selective inhibitor
that targets the fms-like tyrosine-kinase 3 (FLT3) acti-
vating mutations frequently found in AML, in view of a
possible drug–drug interaction with triazoles.13
Since February 2006, a survey of IFDs in AML
patients undergoing intensive chemotherapy has been
prospectively conducted by a predefined diagnostic
strategy.14 A microbiological laboratory and a radio-
logical service dedicated to patients with haematologi-
cal diseases were available at our centre. In the event
of febrile neutropenia (temperature >38 °C recorded
twice or >38.5 °C recorded once), a baseline diagnos-
tic work-up (BDWU) based on three blood cultures
(Sygnal System, Oxoid, Hants, UK) and other microbi-
ological and radiological exams, if clinically indicated,
was performed. Empirical antibacterial therapy was
started and eventually modified according to the
microbiological or clinical data. Patients with persist-
ing fever after 4 days of antibacterial therapy or
patients with fever relapsing after 48 h of deferves-
cence, as well as patients with other clinical findings
possibly related to an IFD, underwent an intensive
diagnostic work-up (IDWU) that included three blood
cultures, GM serum detection by Platelia Aspergillus
assay (Bio-Rad Laboratories, Marnes-La-Couquette,
France) over three consecutive days, CT of the chest
and other exams as indicated. In the event of a nega-
tive IDWU and persistent fever, the IDWU was
repeated. A positive GM test result was defined as an
optical density index of ≥0.5 in two consecutive
samples or ≥0.7 in a single sample in serum and ≥1 in
bronchoalveolar lavage.
In patients with radiological evidence potentially
related to a PFI and negative microbiological exams
(cultures and GM), they were repeated from serum or
respiratory specimen as indicated. Mould-active anti-
fungal therapy (voriconazole or liposomal ampho-
tericin B) at standard recommended doses was started
on first documentation or suspect of PFI. Response to
antifungal therapy was defined as complete or partial
if a >90% or between 50% and 90% reduction in size
of the pulmonary lesions was obtained within
3 months from the diagnosis respectively.15
All patients fulfilling the following criteria were con-
sidered in the analysis:
• Documentation at BDWU or IDWU of any type of
pulmonary lesion at CT examination. The lesion
should not have been already documented at the base-
line CT scan.
• Cultural isolation of filamentous fungi or Geotrichum
capitatum16 from BAL or sputum and/or GM detection
from serum or BAL.
• No microbiological evidence of other pathogens
potentially related to the pulmonary infection.
The Standard glossary of CT imaging definitions was
used to classify pulmonary lesions.17 According to
revised EORTC/MSG definitions only dense and well-
circumscribed lesions with or without halo sign, air
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crescent sign or cavity were considered specific for
a diagnosis of probable PFI.5 Conversely, not well-
circumscribed consolidations, ground glass opacities
and small airways lesions were not considered specifi-
cally diagnostic for a probable PFI. With regard to nod-
ules, although the revised EORTC/MSG definitions did
not differentiate the pulmonary lesions according to
their size, there is no general agreement in considering
micronodules (<1 cm in diameter) as radiological find-
ings fulfilling the EORTC-MSG criteria.11 Therefore, in
our analysis we considered single or multiple millime-
tre pulmonary lesions as aspecific radiological findings.
Two independent radiologists (FM and SV), blind of
the clinical and radiological results, randomly re-eval-
uated all CT Scans at first documentation of PFI (T0)
and classified the radiological findings. Cases were con-
sidered ‘probable PFI’ (group A) when radiological
findings fulfilled the EORTC-MSG criteria5 or ‘pre-
sumed PFI’ (group B) when other aspecific radiological
findings were documented. Then the two observers
blindly re-evaluated the CT exams performed in
patients of groups B within 4 weeks from T0 (T1),
when available, to monitor the possible evolution of
the aspecific pulmonary lesions in specific lesions. In
case of disagreement (for both T0 and T1) a consensus
was reached after discussion.
Variables considered included age, sex, antifungal
prophylaxis, type of chemotherapy cycle, radiological
and microbiological findings, response to antifungal
therapy and survival at 1 and 3 months. The endpoint
of this study was to compare the variables of the group
A and of the group B. Categorical data were analysed
using v2 or Fisher’s exact tests as appropriate, and con-
tinuous variables were compared using T- test. Cumu-
lative survival curves was calculated using the
Kaplan–Meier method and compared by the log-rank
test, taking into account the date of diagnosis of PFI
and the date of death or last follow-up, censored at
3 months after the diagnosis of PFI. All analyses were
performed using SPSS statistical software, version 17.0
for Windows (SPSS, Armonk, NY, USA). P ≤ 0.05 was
considered to be statistically significant. Inter-observer
agreement between the independent reading of the two
radiologists was calculated for both T0 and T1.
Results
During the 8-year period, 265 consecutive patients
were diagnosed with AML and submitted to intensive
chemotherapy. Out of 138 patients with a pulmonary
infiltrate documented at CT examination, 73 patients
fulfilling the above criteria of Group A or Group B PFI
were considered for the analysis. In all cases the infec-
tion was documented within 3 weeks from the admin-
istration of chemotherapy while the patient was
severely neutropenic (absolute neutrophil
count < 100 cmm1). The demographic, clinical, radi-
ological and microbiological manifestations, and 1 and
3 month survival of patients from the first evidence of
PFI are detailed in Table 1.
Overall, 24 (32.9%) patients presented at first evi-
dence of PFI with radiological findings not fulfilling
the EORTC-MSG definitions (group B). No statistically
significant difference was observed for all the analysed
characteristics between the two groups, with the
exception of infection by mucormycetes which were
observed only in the group B (3 of 24 vs. 0 of 49,
P = 0.03). The radiological findings more frequently
observed at diagnosis in group A were macronodules
or well-circumscribed consolidations with halo sign
(27 of 49 cases, 55.1%), whereas not well-circum-
scribed consolidations were found in the majority of
group B (13 of 24 cases, 54.2%). We found no corre-
lation between the type of microbiological documenta-
tion (GM from serum, GM from BAL, Aspergillus
culture isolation) and the different radiological findings
of cases of IPA.
Voriconazole was the most frequently used primary
treatment for PFI and treatment practices did not differ
in the two groups. The 3 months response to antifun-
gal therapy and cumulative survival of the two groups
at 1 and 3 months evaluation were comparable.
Evolution of radiological aspecific findings was moni-
tored in 21 of 24 patients of the group B (in 3 patients
who early died radiological control was not performed).
The early aspecific radiological findings (T0), at a repeat
imaging (T1) changed into specific findings diagnostic
of probable PFI in 11 (52.4%) patients, a median of
10 days (range, 5–28 days) after T0 (Table 2) (Fig. 1).
Macronodule/well-circumscribed consolidation without
halo sign represented the most frequent radiological
finding specific of PFI at Time 1. An evolution in cavity
or air crescent sign lesions was observed in 2 of 13
(15.4%) consolidations and in 2 of 4 (50%) micronodu-
lar lesions. In the 21 patients of the group B evaluable
for radiological evolution, we found no difference (con-
sidering age, sex, previous antifungal prophylaxis and
leukaemia phase) between the 11 patients who later
developed specific radiological findings and the 10
patients who did not. Furthermore, in 17 patients of the
group B with a diagnosis of probable aspergillosis, we
found no correlation between previous antifungal pro-
phylaxis, microbiological characteristics, antifungal
therapy and radiological evolution (Table 3).
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Overall, radiological findings fulfilled the EORTC-
MSG criteria in 49 of 73 (67.1%) patients at T0 and
in 60 of 70 (85.7%) evaluable patients considering
also T1. In the remaining 10 evaluable patients of the
group B without a specific radiological evolution, a
complete or partial regression of pulmonary lesions
with antifungal therapy was obtained in six cases. In
three patients with large pulmonary consolidations
and isolation of mucormycetes, the diagnosis was
confirmed histologically (in 2 cases at autopsy) but the
radiological findings continued to not fulfil the
EORTC/MSG criteria at the following radiological
controls.
Inter-rater agreement between the two Radiologists
was very good: at T0 k was = 0.858 (SE 0.061,
95% CI 0.739–0.978); at T1 k was 0.915 (SE
0.048, 95% CI 0.821–1.000). At T0 discordance
was found in five cases, at T1 discordance was
Characteristic at diagnosis
Group A
(n = 49)
Group B
(n = 24) P
Sex, no. of male (%) 31 (63.3) 14 (58.3) 0.8
Age, median years (range) 53 (24–73) 54 (30–72) 0.9
Type of chemotherapy, no. of cases (%)
First induction 37 (75.5) 17 (70.1) 0.7
Consolidation 6 (12.2) 2 (8.3)
Re-induction/salvage therapy 6 (12.2) 5 (20.1)
Microbiological diagnosis
Aspergillus 46 (93.9) 19 (79.2) 0.1
Mucormycetes 0 3 (12.5) 0.03
Geotrichum capitatum 1 (2.2) 2 (8.3) 0.2
Aspergillus plus Mucormycetes 1 (2.2) 0 1
Aspergillus plus G. capitatum 1 (2.2) 0 1
Posaconazole prophylaxis, no. of cases (%) 21 (42.9) 10 (41.7) 1
Radiological findings, no. of cases (%)2
EORTC-MSG-specific findings
Macronodule/well-circumscribed
consolidation with halo sign
27 (55.1) 0 NP
Macronodule/well-circumscribed
consolidation without halo sign
18 (36.7) 0
Cavity or air crescent sign 4 (8.2) 0
Aspecific findings
Not well-circumscribed consolidation 0 13 (54.2)
Ground-glass opacity 0 4 (16.7)
Micronodules 0 6 (25.0))
Tree in bud 0 1 (4.2)
Mycologic criteria, no. of cases (%)
GM from serum 40 (81.6) 17 (70.8) 0.4
GM from BAL or sputum 5 (10.2) 4 (16.7) 0.5
Culture from BAL or sputum 6 (12.2) 6 (25.0) 0.2
Serum GM peak, median value (range) 1.1 (0.6–4.4) 1.0 (0.5–5) 0.7
Primary antifungal treatment, no. of cases (%)
Voriconazole 37 (75.5) 15 (62.5) 0.3
Liposomal Amphotericin B 10 (20.4) 6 (25.0) 0.8
No antifungal therapy due to early death 2 (4.1) 3 (12.5) 0.3
Complete/partial response after 3
months antifungal therapy;
no. of cases (%) out of pts who
received antifungal therapy
36 (73.5) 19 (79.2) 0.8
1 month cumulative survival, % 77.5 83.3 0.5
3 month cumulative survival, % 67.3 75.0 0.4
GM, galactomannan; NP, statistical comparison was not performed because by definition
the two groups had been stratified according to different radiological findings.
1EORTC-MSG radiological criteria of pulmonary fungal infection were: dense, well-
circumscribed lesions with or without halo sign, air crescent sign and cavity.
2In each patient more than one radiological finding may have been observed at CT
examination but only the predominant finding was indicated.
Table 1 Clinical, radiological and micro-
biological findings among patients with
acute myeloid leukaemia and pulmonary
fungal infection (PFI): comparison of
cases by EORTC-MSG prespecified radio-
logical criteria (Group A)1 vs. cases with-
out prespecified radiological findings
(Group B) at diagnosis.
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found in three cases. Disagreement was observed
only in case with CT observation of well-circum-
scribed consolidation and macronodules: in all cases
a final consensus was reached between the two
radiologists.
Discussion
The definitions of PFI according to the EORTC-MSG
criteria are considered a standard in the clinical trials
and in the epidemiological studies, particularly in
Table 2 Evolution of radiological findings at a repeat imaging in 21 patients with pulmonary infiltrates not fulfilling the EORTC-MSG
radiological criteria at diagnosis of presumed pulmonary fungal infection.
Radiological findings at diagnosis
Evolution of radiological findings, n (%)
Macronodule/well-circumscribed
consolidation
Macronodule/well-circumscribed
consolidation with halo sign
Cavity or air
crescent sign
No specific
evolution
Not well-circumscribed consolidation, 13 pts1 4 (30.8) 0 2 (15.4) 7 (53.8)1
Micronodules, 4 pts 1 (25) 0 2 (50) 1 (25)
Ground glass. 3 pts 1 (33.3) 0 0 2 (66.6)
Tree in bud, 1 pt 1 (100) 0 0 0
13 pts with a diagnosis of presumed pulmonary mucormycosis (later histologically proven): no specific evolution in all cases.
Figure 1 Cases of pulmonary fungal infections with aspecific radiological findings at first documentation (T0) and evolution in specific
radiological findings at re-evaluation (T1). (a) A micronodular lesion at T0 (arrow) and a nodular lesion at T1 (day +5). (b) A micron-
odular lesion at T0 (arrow) and an air crescent sign lesion at T1 (day +8). (c) A consolidation at T0 and an air crescent sign lesion at
T1 (day +9). (d) A mass with air bronchogram at T0 and a cavity lesion at T1 (day +11).
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immunocompromised populations at very high infec-
tious risk such as AML patients.4,5 The revised defini-
tions published in 2008 restricted the radiological
criteria of PFI as compared to those of the original def-
initions published in 2002 where any kind of pul-
monary infiltrate was considered.4,5 Indeed, it is
common experience that the strict application of these
definitions may exclude PFI with radiological findings
other than well-circumscribed lesions with or without
halo sign, air crescent sign and cavity, regardless of
the microbiological documentation. The Consensus
Group of the EORTC/MSG did not consider their defini-
tions a substitute for complete clinicopathological
descriptions and classifications of IFD, and acknowl-
edged that the failure to meet the criteria for IFD does
not mean that there is no IFD, only that there is insuf-
ficient evidence to support the diagnosis.5 However,
the EORTC/MSG Consensus Group suggested to apply
them with the primary goal of fostering communica-
tion, furthering our understanding of the epidemiology
and evolution of IFD, and facilitating our ability to test
the efficacy of therapeutic regimens and strategies.5
The use of restrictive, specific diagnostic criteria in
studies aimed at the evaluation of the efficacy of new
antifungal treatments may be acceptable considering
the importance of a careful evaluation of alternative
strategies in the management of severe IFDs and the
comparability of clinical trials, but the application of
insensitive diagnostic criteria in the detection of epi-
demiological trends or in the evaluation of prevention
strategies is likely to lead an underestimation of the
phenomenon with a potentially deleterious impact on
some practices as the definition of the infectious risk
and the indication for primary prophylaxis. It should
be also considered that, in the absence of other
shared criteria more suitable for clinical practice, the
EORTC/MSG definitions represent a ‘de facto’ standard
in the real life and in the daily communication
between physicians.
A revision of the EORTC-MSG definitions with the
inclusion of a new category of IPA giving a greater
weight to Aspergillus-specific microbiological criteria
has been proposed by Nucci et al. [10] based on a ret-
rospective study from the Myeloma Institute for
Research and Therapy, University of Arkansas for
Medical Sciences, which showed that the features of
multiple myeloma patients with probable IPA accord-
ing to the revised EORTC/MSG radiological criteria are
comparable to those of patients without specific radio-
logical findings. About 30% of 116 episodes of IPA,
presented with radiological findings not fulfilling the
above specific diagnostic criteria of probable IPA and
no significant difference in the host, clinical and myco-
logical characteristics, as well as in survival, was
observed in the two groups. In a recently published
experience from our Institution, we confirmed these
results in 109 patients affected by various haematolog-
ical malignancies or submitted to allogeneic stem cell
transplant with pulmonary infections associated to
culture isolation of Aspergillus and/or GM detection.11
In this study, which includes 46 AML patients
already evaluated in the previous series, we expanded
the population of AML patients and we considered also
patients with isolation of non-Aspergillus fungi. A
focus on the frequency and the evolution of some radi-
ological pictures (i.e. not well-circumscribed consolida-
tions, ground glass opacities, micronodules, tree in
bud) different from those considered in the EORTC/
MSG definitions was also performed.
Our results seem to further confirm that pulmonary
infiltrates other than those defined specific for PFI,
when associated to a microbiological documentation,
Mycologic and
therapeutic variables
Specific evolution of
radiological findings, n = 11
No specific evolution of
radiological findings, n = 6
Posaconazole prophylaxis,
no. of cases (%)
4 (36.4) 2 (33.3)
Mycologic criteria, no. of cases (%)
GM from serum 10 (91) 5 (83.3)
GM from BAL or sputum 2 (18) 1 (16.6)
Culture from BAL or sputum 1 (9) 1 (16.6)
Serum GM peak,
median value (range)
0.9 (0.5–3.8) 1.2 (0.6–5)
Primary antifungal therapy, no. of cases (%)
Voriconazole 9 (81.8) 5 (83.3)
Liposomal Amphotericin B 2 (28.2) 1 (16.7)
GM, galactomannan.
Table 3 Microbiological characteristics,
antifungal treatment and evolution of
radiological findings in 17 patients with
pulmonary infiltrates not fulfilling the
EORTC-MSG radiological criteria at
diagnosis of presumed pulmonary
aspergillosis.
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should be considered probably diagnostic of a fungal
disease in high-risk AML neutropenic patients. The
two PFI groups did not significantly differ in the host,
clinical and mycological characteristics, in the
response to antifungal therapy, and in the outcome.
Half of pulmonary radiological pictures in the pre-
sumed PFI group (Group B), including micronodules,
evolved in large well-circumscribed or cavity lesions
after few days suggesting that these cases might be an
early phase of the disease (Fig. 1), furthermore, three
cases of mucormycosis, later confirmed hystologically,
presented with large unspecific consolidations which
maintained the same aspecific findings at the following
radiological controls. Of interest, even though the
inter-rate agreement between the two expert radiolo-
gists was very good, a slight discordance was still pre-
sent between the two most frequently observed
radiological findings: macronodules and consolidation.
Thus, our results seem to show that the size and
appearance of the pulmonary lesion does not represent
a criterion for differentiating the diagnostic suspect of
PFI. The two groups did not differ in the rate of previ-
ous posaconazole primary prophylaxis, furthermore,
since we used posaconazole prophylaxis in AML
patients at our institution, while observing a relevant
reduction in the rate of PFIs, we did not detect signifi-
cant changes in the clinical features of such complica-
tions. False-positive results may be observed when
using the GM assay and serum positivity in absence of
a proper clinical suspicion of PFI should be considered
with caution. In our experience, GM assay was not
used as a surveillance of asymptomatic patients along
the period at risk but in the context of a clinically
driven strategy. This approach proved to offer a 90%
positive predictive value regardless of the use of anti-
fungal prophylaxis.18 The performance of the microbi-
ological diagnostic strategy did not differ according to
the radiological presentation of the pulmonary infil-
trates. GM represented the main microbiological
diagnostic tool and no significant difference in the
serum level of the antigen was observed in the two
groups.
In conclusion, our study shows that in AML
patients submitted to intensive chemotherapy a large
proportion of PFIs may present with radiological fea-
tures not fulfilling the EORTC-MSG definitions, reflect-
ing the fact that such fungal diseases may present in
atypical form not only in patients with chronic lym-
phoprolipherative disorders but also in acute leukae-
mia.10,11 The different radiological presentation of the
pulmonary infiltrates (considering type, number and
size) and their evolution was not associated to the use
of antifungal prophylaxis and did not correlate with
specific microbiological documentation or antifungal
treatment.
Considerable uncertainty and controversy exists
regarding the best method for establishing a diagnosis
of PFI in high-risk haematological patients. We think
that appropriate microbiological evidence of a fungal
aetiology in high-risk patients may support the possi-
bility to revise the current EORTC/MSG definitions
extending the radiological suspicion of PFI to less tra-
ditional chest CT findings, including not well-circum-
scribed consolidations, micronodules, ground glass
opacities and other small airway lesions. The more
specific radiological criteria considered in the EORTC/
MSG definitions, eventually with the addition of the
recently described ‘reversed halo sign’ and ‘hypodense
sign’,19,20 should be probably preferred in clinical tri-
als (i.e. primary or salvage antifungal therapy) where
a high level of diagnostic accuracy is requested. On
the other hand, more sensitive, although less specific,
criteria are needed in other settings (i.e. epidemiologi-
cal or prophylaxis studies) to avoid a misleading
underestimation of diagnoses.
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